(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






2 Result: Immutep

Enveric Biosciences Soars on EVM201 Series Potential, Immutep Surges on Clinical Trial Findings, Buy Rating for IDEAYA Biosciences

May 24th, 2023

Enveric Biosciences, Inc. (Nasdaq: ENVB) said that has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for another patent application involving its EVM201 Series The soon-to-issue patent, titled "C4-Carbox. Read more

Immutep's Eftilagimod Alpha Shows Promise in Phase II Trial, Lightning eMotors Reports Q1 Loss and $50M Pre-Paid Advance Deal, BioNTech Upgraded to Buy

May 17th, 2023

Immutep Limited (Nasdaq: IMMP) has received positive feedback from the US Food and Drug Administration (FDA) for its late-stage clinical development plans for Eftilagimod Alpha ("efti") in the treatment of 1st line non-small cell lung cancer. In addi. Read more

Load More Content